Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer’s disease
Authors:
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Brain Research
- Vol. 1699, 117-120
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81200877)
- Medical Science and Technology Development Foundation of Nanjing (YKK17287)
This publication has 21 references indexed in Scilit:
- Synergic interaction between amyloid precursor protein and neural cell adhesion molecule promotes neurite outgrowthOncotarget, 2016
- Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluidsExpert Review of Proteomics, 2015
- Soluble Amyloid Precursor Protein 770 Is Released from Inflamed Endothelial Cells and Activated PlateletsJournal of Biological Chemistry, 2012
- Selective Interaction of Amyloid Precursor Protein with Different Isoforms of Neural Cell Adhesion MoleculeJournal of Molecular Neuroscience, 2011
- Is Timed Up and Go Better Than Gait Speed in Predicting Health, Function, and Falls in Older Adults?Journal of the American Geriatrics Society, 2011
- Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairmentNeurobiology of Aging, 2006
- CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatmentExpert Review of Molecular Diagnostics, 2005
- Neural cell adhesion molecule in human serum. Increased levels in dementia of the Alzheimer typeNeurobiology of Disease, 2004
- Disturbances in cell recognition molecules (N-CAM and L1 antigen) in the CSF of patients with schizophreniaExperimental Neurology, 1995
- The expression of an N-CAM serum fragment is positively correlated with severity of negative features in type II schizophreniaBiological Psychiatry, 1988